A5013475736- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Hemoglobinopathies and Related Disorders
- Colorectal Cancer Treatments and Studies
- Pharmaceutical studies and practices
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- Biomedical Text Mining and Ontologies
- Machine Learning in Healthcare
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Drug Transport and Resistance Mechanisms
- Breast Cancer Treatment Studies
- Pharmaceutical Economics and Policy
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Occupational and environmental lung diseases
- Complement system in diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hematopoietic Stem Cell Transplantation
- Vascular Malformations Diagnosis and Treatment
- Bacterial Genetics and Biotechnology
- CAR-T cell therapy research
Novartis (Switzerland)
2021-2024
Roche (Switzerland)
2016-2019
Karolinska Institutet
2015
KTH Royal Institute of Technology
2015
Background Randomized phase III trials have established the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as first-line treatment for EGFR mutation-positive advanced non–small-cell lung cancer (EGFR Mut+ NSCLC). This retrospective cohort study examined management patterns and outcomes patients with NSCLC in a real-world setting. Materials methods Data were extracted from US Flatiron Electronic Health Record-derived database. Adult stage IIIB/IV (exon 19...
The ruxolitinib compassionate use (CU) program offered to patients ≥2 years of age with confirmed steroid-resistant acute or chronic graft-versus-host disease (aGvHD and cGvHD, respectively). Data from 1180 (n = 775, 370 35 aGvHD, non-specified GvHD, respectively) were analyzed. Most had severe cGvHD (56%) stage III/IV aGvHD (70%) previously received corticosteroids ( > 80%); was requested primarily as a second-/third-line option. Patients <12 ≥12 old most often the recommended doses (5 mg...
The efficacy of bevacizumab (BEV) in elderly patients with glioblastoma remains unclear. We evaluated the effect BEV on survival this patient population using Survival, Epidemiology, and End Results (SEER)-Medicare database.
Abstract Single-particle reconstruction (SPR) and electron crystallography (EC), two major applications in microscopy, can be used to determine the structure of membrane proteins. The three-dimensional (3D) map is obtained from separated particles conventional SPR, but periodic unit cells EC. Here, we report a refined SPR procedure for processing 2D crystal images. method applied crystals melibiose permease, secondary transporter Escherichia coli . current improved our previously published...
8554 Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer, which may be challenging to diagnose. The standard of care for MPM cisplatin plus pemetrexed. In the recent phase III MAPS trial, addition bevacizumab provided significant survival benefit. There limited data on real-world treatment patterns provide context trial results. Consequently, present study was conducted evaluate and referral patterns, co-morbidities resource use in patients with U.S. Methods:...
OBJECTIVE:To evaluate the association between timing of adjunctive anti-epilepsy drug (AED) initiation, and all-cause epilepsy-related hospitalization rates among patients with without Partial-onset Seizures (POS). BACKGROUND:Early achievement epilepsy control has potential to avoid complications costs. DESIGN/METHODS:The MarketScan® database was used analyze patterns (Jan-2006 Dec-2011) for adult 蠅1 diagnosis code EP (ICD-9 345.xx:[partial-onset seizures: 345.4x, 345.5x, 345.7x]). Included...
OBJECTIVE: To evaluate patient characteristics associated with treatment discontinuations and switches among patients epilepsy. BACKGROUND: Despite the availability of multiple anti-epileptic drugs (AEDs), around 40[percnt] experience uncontrolled These are predisposed to severe health risks, impaired quality life higher healthcare costs (Sperling 2004, Manjunath 2012). Few studies have investigated reasons for AED switching discontinuation. DESIGN/METHODS: The RealHealthData medical...
OBJECTIVE: To evaluate the healthcare and societal economic burden of adjunctively-treated patients with uncontrolled epilepsy. BACKGROUND: Approximately 4 in 10 experience epilepsy despite treatment. These are predisposed to severe health risks, impaired quality life higher costs. DESIGN/METHODS: The MarketScan® retrospective database was used analyze direct indirect costs (Jan-2006 Dec-2011) for epilepsy. Patients had 蠅1 diagnosis code (ICD-9 345.xx), 蠅18 years, add-on antiepileptic drug...
Limited information on systemic treatment and outcome in elderly patients with glioblastoma is available. Since the 2009 accelerated FDA approval of bevacizumab as a single-agent therapy for adult recurrent glioblastoma, bevacizumab-based regimens have become standard care this setting. The objective analysis was to evaluate effect use survival using population-based database. We analyzed Surveillance, Epidemiology, End Results (SEER) Medicare database aged >65 years diagnosed primary...
In this study, we introduce ExBEHRT, an extended version of BEHRT (BERT applied to electronic health records), and apply different algorithms interpret its results. While considers only diagnoses patient age, extend the feature space several multimodal records, namely demographics, clinical characteristics, vital signs, smoking status, diagnoses, procedures, medications, laboratory tests, by applying a novel method unify frequencies temporal dimensions features. We show that additional...
Topic: 12. Bone marrow failure syndromes incl. PNH - Clinical Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematological disorder characterized by intravascular hemolysis (IVH), thrombophilia and bone (BMF). clinically heterogeneous, hospitalization regular transfusions may be needed. Treatment with currently approved C5 inhibitors (C5i), eculizumab ravulizumab, have shown efficacy in IVH control reduction thrombosis risk. Despite C5i therapy, many patients (pts)...
Corticosteroids are widely used by patients with glioblastoma (GBM) to control oedema and radiotherapy (RT)-/chemotherapy (CT)-induced side effects. However, corticosteroid use is associated its own potentially serious Bevacizumab (BEV) has become the current standard therapy for recurrent GBM in USA. Clinical trials have suggested that BEV a corticosteroid-sparing effect GBM. We aimed evaluate this elderly newly diagnosed treated real-world setting. In retrospective, population-based study,...
Background: Despite advances in screening, management and treatment, gaps remain our understanding of sickle cell disease (SCD) the real-world setting. Most observational studies rely on structured data (ie predefined clinical concepts such as ICD9/10 codes) from electronic medical records (EMRs), but this neglects clinically relevant information stored unstructured narrative sections physician notes. Advances analytic methods allow for combination notes data, potentially providing a more...